Literature DB >> 8099611

Human Kupffer cells infected with HIV-1 in vivo.

F T Hufert1, J Schmitz, M Schreiber, H Schmitz, P Rácz, D D von Laer.   

Abstract

Blood monocytes as well as cells of the macrophage-phagocytic system in several tissues are targets for HIV-1 in vivo and in vitro. However, the data on HIV-1 infection of liver macrophages/Kupffer cells (KCs), which make up the main pool of fixed-tissue macrophages, is controversial. We therefore studied HIV-1 infection of KCs in vivo. Blood and liver tissue was obtained from seven AIDS patients shortly after death. Liver tissue was minced before processing. Cell suspensions were further purified by density gradient centrifugation, stained with anti-CD14 (blood monocytes) or anti-macrophage 25F9 (KCs), and separated by fluorescence-activated cell sorting (FACS). These highly purified cell populations were then analyzed for HIV-1 proviral DNA by the polymerase chain reaction (PCR). By performing PCR on FACS-purified cell populations, we could show that both KCs and peripheral blood monocytes were HIV-1-infected in 3 of 7 patients. KCs harbored HIV-1 proviral DNA only if peripheral blood monocytes were infected. These data show that KCs of the liver are infected with HIV-1 in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099611

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  39 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

3.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

Review 4.  Redefining the viral reservoirs that prevent HIV-1 eradication.

Authors:  Evelyn Eisele; Robert F Siliciano
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

Review 5.  HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Authors:  Paul R Gorry; Nicholas Francella; Sharon R Lewin; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2013-10-24       Impact factor: 4.962

6.  Analysis of HIV quasispecies suggests compartmentalization in the liver.

Authors:  Patricia K Penton; Jason T Blackard
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

7.  Kinetics of liver macrophages (Kupffer cells) in SIV-infected macaques.

Authors:  Muhammad H Ahsan; Amy F Gill; Xavier Alvarez; Andrew A Lackner; Ronald S Veazey
Journal:  Virology       Date:  2013-08-19       Impact factor: 3.616

Review 8.  Aging of the Liver: What This Means for Patients with HIV.

Authors:  Austin W Chan; Yuval A Patel; Steve Choi
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

9.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution.

Authors:  Ashwin Balagopal; Stuart C Ray; Ruben Montes De Oca; Catherine G Sutcliffe; Perumal Vivekanandan; Yvonne Higgins; Shruti H Mehta; Richard D Moore; Mark S Sulkowski; David L Thomas; Michael S Torbenson
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.